Why Is This Cannabis Stock Up 62%?

OrganiGram Holdings Inc (TSXV:OGI) isn’t as popular as Green Organic Dutchman Holdings Ltd (TSX:TGOD) or Hexo Corp (TSX:HEXO), but it has a similar valuation. Is this a hidden gem or purely hype?

Despite having a share price of just $0.23 in 2015, OrganiGram Holdings Inc (TSXV:OGI) stock has quickly risen to a market cap of more than $1.3 billion. Since the start of 2019, shares are up another 62%.

Now with a valuation that rivals other notable pot stocks like Green Organic Dutchman Holdings Ltd (TSX:TGOD) and Hexo Corp (TSX: HEXO), why do shares seem to consistently move higher by large jumps every month? Is the latest 62% rise due to improving fundamentals or pure hype?

The optimism is warranted

As Fool contributor Keith Speights wrote in September, “OrganiGram hasn’t generated as much buzz as bigger Canadian marijuana stocks. But that might not be a bad thing.”

Since that article, shares have popped more than 100%. It seems that OrganiGram is finally getting the hype that nearly every other cannabis-related stock has received.

As with its competitors, OrganiGram is promoting its strong growth opportunities across Canada, as well as its leading cost position. Those are advantages that are found in every investor presentation across the entire industry. OrganiGram seems to be able to back the claims, however.

As a cannabis producer, OrganiGram is focused on ramping and expanding its three-level, indoor growing facility located in New Brunswick. By the end of 2019, production should hit 113,000 kilograms on an annualized basis, up from 36,000 kilograms at the start of the year. Green Organic Dutchman, by comparison, will only bring 14,000 kilograms of cannabis online this year.

OrganiGram is also one of only three companies with licensing agreements in all ten provinces. Management has been putting the pieces into place to capitalize on international growth opportunities as well.

In total, OrganiGram looks like an ideal way to capitalize on the cannabis boom. But what about the valuation?

Now it gets interesting

With less name recognition, it’s reasonable to be wary of OrganiGram’s $1.3 billion valuation, especially as better-known peers like Green Organic Dutchman and Hexo trade in a similar range. Looking at the fundamentals, however, OrganiGram is a relative bargain.

First, the company has enough cash on hand to fund its expansion plans this year, so dilution won’t be as necessary. Second, shares are simply a steal versus the rest of the cannabis industry.

Based on 2019 consensus estimates, the average cannabis stock trades at 226x EBITDA. OrganiGram stock trades at just 22x this year’s EBITDA.

Looking further ahead, the steep valuation gap remains. The average peer now trades at 53x 2020 EBITDA while OrganiGram is valued at just 14x EBITDA.

With a skilled management team, solid balance sheet, and reasonable growth targets, it’s tough to justify such a discounted valuation.

Your best bet?

If the cannabis market continues to take off, OrganiGram stock looks like a steal compared to competitors like Green Organic Dutchman and Hexo. Even if industry hype recedes, OrganiGram’s valuation has less room to contract.

Today, OrganiGram appears like a great way to play the cannabis market, even after its recent 62% run.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

Top Canadian Stocks to Buy Right Now With $1,000

Cannara, Source Energy and CareRx just updated investors. See what $1,000 can buy in these Canadian stocks, plus the risks…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf’s Takeover Bid for Aurora Cannabis: What Investors Need to Know

Curaleaf's takeover bid for Aurora Cannabis offers a premium but brings stock, debt, and deal risks. Here’s what ACB investors…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

It's appealing directly to the Canadian company's shareholders with a cash-and-stock offer.

Read more »

runner checks her biodata on smartwatch
Cannabis Stocks

Average TFSA and RRSP Balances at Age 45: Are You on Par?

Most 45-year-olds have less than $100,000 combined in their TFSA and RRSP. Here's how TerrAscend could help you close the…

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

Cannabis stocks look risky because price wars, dilution, and regulation can turn one weak quarter into a long drawdown.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »